CryoPort Inc.: Growth in Commercial Cell and Gene Therapies - Analysts Raise Their Ratings!
Reading Time: 3 minutes
CryoPort Inc. (CYRX) presented its Q2 report after market hours on August 5. According to the report, revenues increased by 14.5% compared to the same period last year, reaching $45.45 million, and the EPS improved from -$0.29 to -$0.24. Notably, the revenue in the commercial cell and gene therapy segment saw significant growth, reflecting the increasing development and adoption of these therapies. Analysts had expected revenue of only $41.74 million, while they had precisely calculated the EPS to be -$0.24. The growth in Q2 2025 was broad-based...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
